Navidea Biopharmaceuticals, Inc.
NAVB
$0.0001
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -- | 508.58% | 57.61% | 38.99% | -90.29% |
| Total Depreciation and Amortization | -- | -1.81% | 4.15% | 7.29% | 13.30% |
| Total Amortization of Deferred Charges | -- | 14.10% | 14.25% | 14.14% | 25.80% |
| Total Other Non-Cash Items | -- | 114.12% | -575.10% | 129.74% | 13.77% |
| Change in Net Operating Assets | -- | -309.80% | 11.15% | -80.78% | 428.91% |
| Cash from Operations | -- | 372.37% | 29.22% | -30.95% | 13.15% |
| Capital Expenditure | -- | 100.00% | -- | 100.00% | -118.18% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -168.72% | 66.25% | -11.63% | 43.72% |
| Cash from Investing | -- | -64.97% | 45.28% | 8.75% | 34.90% |
| Total Debt Issued | -- | -- | -- | -100.00% | -33.33% |
| Total Debt Repaid | -- | -151.62% | -209.89% | -- | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 96.36% | -6,497.95% |
| Cash from Financing | -- | 840.45% | -100.90% | -101.61% | 352.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | 411.41% | 24.68% | -160.96% | 580.58% |
